PT  - JOURNAL ARTICLE
AU  - L B Johnston
AU  - M O Savage
TI  - Should recombinant human growth hormone therapy be used in short small for gestational age children?
AID  - 10.1136/adc.2003.034785
DP  - 2004 Aug 01
TA  - Archives of Disease in Childhood
PG  - 740--744
VI  - 89
IP  - 8
4099  - http://adc.bmj.com/content/89/8/740.short
4100  - http://adc.bmj.com/content/89/8/740.full
SO  - Arch Dis Child2004 Aug 01; 89
AB  - Short small for gestational age (SGA) children represent 20% of all children with short stature1 and therefore constitute a significant portion of the caseload in a growth clinic. The recent approval of recombinant human growth hormone (GH) for the treatment of short stature in SGA children by the European Union’s Committee on Proprietary Medicinal Products offers a new licensed therapeutic option. This article examines the role of GH therapy in short SGA children with particular reference to selection of patients, effectiveness, safety, and its potential metabolic implications.